BUZZ-Emergent BioSolutions rises on disclosing $400 mln in orders through 2025

Reuters

Sep 25, 2024

** Shares of Emergent BioSolutions rise 12.6% to $6.88 premarket

** Co says it has secured about $400 mln in orders for 2024 and 2025 for its vaccinia virus, smallpox and mpox vaccines

** EBS says this includes the previously disclosed contract from the U.S. government to procure the vaccines, valued at more than $250 mln

** Says to date in 2024, customer orders of nearly $210 mln have been delivered for ACAM2000 - its smallpox and mpox vaccine - and CNJ-016 - its vaccine for vaccinia virus

** For the remainder of 2024 and into 2025, co says it is confirmed to deliver over $185 mln in ACAM2000 and CNJ-016 orders

** Up to last close, stock more than doubled YTD

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2470259600"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2470259600\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2470259600?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-25 20:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2470259600","market":"us","top_or_hot":-1,"title":"BUZZ-Emergent BioSolutions rises on disclosing $400 mln in orders through 2025","media":"Reuters","content":"<html><body><p>** Shares of Emergent BioSolutions    rise 12.6% to $6.88 premarket </p><p>   ** Co says it has secured about $400 mln in orders for 2024 and 2025 for its vaccinia virus, smallpox and mpox vaccines  </p><p>   ** EBS says this includes the previously disclosed contract from the U.S. government to procure the vaccines, valued at more than $250 mln </p><p>    ** Says to date in 2024, customer orders of nearly $210 mln have been delivered for ACAM2000 - its smallpox and mpox vaccine - and CNJ-016 - its vaccine for vaccinia virus</p><p>   ** For the remainder of 2024 and into 2025, co says it is confirmed to deliver over $185 mln in ACAM2000 and CNJ-016 orders</p><p>   ** Up to last close, stock more than doubled YTD </p><p> (Reporting by Sneha S K)</p><p>((Sneha.SK@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Emergent BioSolutions rises on disclosing $400 mln in orders through 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Emergent BioSolutions rises on disclosing $400 mln in orders through 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-09-25 20:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>** Shares of Emergent BioSolutions    rise 12.6% to $6.88 premarket </p><p>   ** Co says it has secured about $400 mln in orders for 2024 and 2025 for its vaccinia virus, smallpox and mpox vaccines  </p><p>   ** EBS says this includes the previously disclosed contract from the U.S. government to procure the vaccines, valued at more than $250 mln </p><p>    ** Says to date in 2024, customer orders of nearly $210 mln have been delivered for ACAM2000 - its smallpox and mpox vaccine - and CNJ-016 - its vaccine for vaccinia virus</p><p>   ** For the remainder of 2024 and into 2025, co says it is confirmed to deliver over $185 mln in ACAM2000 and CNJ-016 orders</p><p>   ** Up to last close, stock more than doubled YTD </p><p> (Reporting by Sneha S K)</p><p>((Sneha.SK@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2470259600","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2470259600","pubTimestamp":1727266912,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"** Shares of Emergent BioSolutions    rise 12.6% to $6.88 premarket    ** Co says it has secured about $400 mln in orders for 2024 and 2025 for its vaccinia virus, smallpox and mpox vaccines     ** EBS says this includes the previously disclosed contract from the U.S. government to procure the vaccines, valued at more than $250 mln     ** Says to date in 2024, customer orders of nearly $210 mln have been delivered for ACAM2000 - its smallpox and mpox vaccine - and CNJ-016 - its vaccine for vaccinia virus   ** For the remainder of 2024 and into 2025, co says it is confirmed to deliver over $185 mln in ACAM2000 and CNJ-016 orders   ** Up to last close, stock more than doubled YTD  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","EBS":"Emergent Biosolutions","BK4583":"猴痘概念"},"translate_title":"BUZZ-Emergent BioSolutions披露到2025年订单将达到4亿美元，股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EBS":1},"content_text":"** Shares of Emergent BioSolutions    rise 12.6% to $6.88 premarket    ** Co says it has secured about $400 mln in orders for 2024 and 2025 for its vaccinia virus, smallpox and mpox vaccines     ** EBS says this includes the previously disclosed contract from the U.S. government to procure the vaccines, valued at more than $250 mln     ** Says to date in 2024, customer orders of nearly $210 mln have been delivered for ACAM2000 - its smallpox and mpox vaccine - and CNJ-016 - its vaccine for vaccinia virus   ** For the remainder of 2024 and into 2025, co says it is confirmed to deliver over $185 mln in ACAM2000 and CNJ-016 orders   ** Up to last close, stock more than doubled YTD  (Reporting by Sneha S K)((Sneha.SK@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}